Physician profile
Ajith Purush
NPI 1699761437
$5,354.81
in general payments reported to CMS, 2019-2025
30 companies · $668 in 2025
The $668 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $753 · 2021: $415 · 2022: $846 · 2023: $886 · 2024: $817 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $798.69 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $771.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $748.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $593.13 | 2019-2025 | Jot Dx, Tendril, Freestyle Libre 2 |
| Amgen INC. | $423.96 | 2019-2025 | Evenity, Prolia, Repatha |
| Sumitomo Pharma America, INC. | $281.87 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $253.47 | 2019-2023 | Xarelto |
| Watermark Medical, INC. | $225.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.63 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $115.77 | 2021-2023 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.47 | 2019-2023 | Synjardy, Tradjenta |
| Astellas Pharma US INC | $102.10 | 2020-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $96.27 | 2019-2024 | Ozempic, Rybelsus |
| Eisai INC. | $95.62 | 2020-2022 | |
| Mylan Specialty L.P. | $82.78 | 2019-2024 | Yupelri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $78.42 | 2019-2022 | |
| Pfizer INC. | $75.24 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $52.70 | 2022 | |
| Esperion Therapeutics, INC. | $48.85 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $44.21 | 2023-2024 | |
| Boston Scientific Corporation | $41.73 | 2019 | |
| Amarin Pharma, INC. | $32.49 | 2020-2021 | |
| Lucid Diagnostics INC. | $22.10 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.23 | 2023 | Quviviq |
| Genentech USA, INC. | $18.63 | 2019 | |
| Ge Healthcare | $16.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.69 | 2025 | Zoryve |
| Alfasigma USA, INC. | $16.48 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.90 | 2022 | |
| Janssen Biotech, INC. | $15.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajith Purush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.